Form 4 for EW Edwards Lifesciences
Accepted 2024-02-15 00:00:00 ET · period of report 2024-02-13 · accession 0001225208-24-002191 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-15 | 2024-02-13+ | EW | Szyman Catherine M. | CVP, Critical Care | S - Sale+OE | $85.98 | -47.0K | 34.8K | -57% | -$4.04M |
| DM | 2024-02-15 | 2024-02-13+ | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $36.75 | +47.0K | 61.8K | +317% | +$1.73M |
| DM | 2024-02-15 | 2024-02-13+ | EW | Szyman Catherine M. | CVP, Critical Care | M - OptEx | $0.00 | -47.0K | 27.0K | -64% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-13 | S | D | 20,000 | $86.46 | 34,813.57 | D | — | — | (F1) This transaction was executed in multiple trades at prices ranging from $86.00 to $86.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2024-02-13 | M | A | 20,000 | $36.75 | 54,813.57 | D | — | — | |
| 3 | Common | Common Stock | 2024-02-15 | M | A | 27,000 | $36.75 | 61,813.57 | D | — | — | |
| 4 | Common | Common Stock | 2024-02-15 | S | D | 27,000 | $85.62 | 34,813.57 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $85.44 to $85.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 5 | Derivative | Employee Stock Option (Right to Acquire) | 2024-02-15 | M | D | 27,000 | $0.00 | 0 | D | $36.75 · 2018-05-11 to 2024-05-10 | 27,000 Common Stock | |
| 6 | Derivative | Employee Stock Option (Right to Acquire) | 2024-02-13 | M | D | 20,000 | $0.00 | 27,000 | D | $36.75 · 2018-05-11 to 2024-05-10 | 20,000 Common Stock |